サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1659424

次世代がん診断の世界市場

Next Generation Cancer Diagnostics

出版日
ページ情報
英文 89 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
次世代がん診断の世界市場
出版日: 2025年02月20日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 89 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

次世代がん診断の世界市場、2030年には米国で646億米ドルに達する見込み

2024年に198億米ドルと推定される次世代がん診断の世界市場は、分析期間2024年から2030年にかけて21.8%のCAGRで成長し、2030年には646億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるqPCR &Multiplexing Technologyは、CAGR 22.8%を記録し、分析期間終了時には282億米ドルに達すると予測されます。次世代シーケンス技術分野の成長率は、分析期間中CAGR 17.9%と推定されます。

米国市場は57億米ドルと推定、中国はCAGR21.0%で成長予測

米国の次世代がん診断市場は、2024年に57億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに99億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは21.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ19.3％と18.0％と予測されています。欧州では、ドイツがCAGR約14.8%で成長すると予測されています。

世界の次世代がん診断市場- 主要動向と促進要因のまとめ

次世代がん診断はどのように腫瘍学に革命を起こしているのか？

次世代がん診断（NGCD）は、様々ながんの早期発見、正確な診断、個別化治療のための高度なツールを提供し、腫瘍学の分野における飛躍的な進歩を象徴しています。これらの診断法は、リキッドバイオプシー、ゲノミクス、プロテオミクス、次世代シーケンシング（NGS）など、幅広い技術を包含しています。従来の診断とは異なり、NGCDは詳細な分子的洞察を提供するため、がん専門医はがんの進行を促す遺伝子変異やバイオマーカーを理解することができます。この正確さによって標的治療が可能になり、患者の転帰を改善し、副作用を減らすことができます。がんの有病率が世界的に上昇する中、NGCDは、より個別化され、より迅速で、より効果的ながん治療を実現することで、がん治療の変革に重要な役割を果たしています。

次世代がん診断市場の主要セグメントは？

主要技術には、リキッドバイオプシー、NGS、プロテオミクス、バイオインフォマティクスツールなどがあり、リキッドバイオプシーとNGSは、非侵襲的な性質と遺伝子変化を検出する能力により大きな支持を得ています。アプリケーションの面では、NGCDはスクリーニング、診断検査、治療反応のモニタリングに使用されています。乳がん、肺がん、大腸がんなどの早期がんのスクリーニングは、早期発見によって生存率が大幅に向上する主要な応用分野です。NGCDの主なエンドユーザーには、病院、診断研究所、研究機関が含まれ、これらすべてが、がん管理の精度と効率を高めるために、これらの技術を臨床ワークフローに統合しています。

NGCDテクノロジーはヘルスケアセクター間でどのように統合されているか？

病院や腫瘍センターでは、特に高リスク患者や遺伝性がん症候群の患者を対象に、NGCDを日常的ながんスクリーニングや診断プロトコールに組み込んでいます。診断研究所はNGCDを使用してゲノムおよびプロテオミクス検査を実施し、特定の変異や治療選択肢の特定を支援し、精密医療を支えています。研究機関は、臨床試験の実施、がんゲノミクスの研究、新薬ターゲットの探索にこれらの診断法を活用しています。製薬会社もNGCD開発者と協力して、薬剤の有効性を予測するバイオマーカーを特定し、それによって薬剤開発を改善し、臨床試験を加速させています。さらに、遠隔医療プラットフォームは遠隔患者モニタリングのためにNGCDを組み込み始めており、がん診断をより身近なものにしています。

次世代がん診断市場の成長を促進する要因は？

次世代がん診断市場の成長は、がんの有病率の増加により、より効果的なスクリーニングや診断ツールに対する需要が高まっていることなど、いくつかの要因によって牽引されています。ゲノミクスとプロテオミクスの進歩による個別化医療へのシフトが、NGCDsの採用にさらに拍車をかけています。リキッドバイオプシー技術の急速な開発は、NGSプラットフォームの改良と相まって診断精度を高め、NGCDを現代の腫瘍学に不可欠なものとしました。また、がん研究や診断技術革新に対する規制当局の承認や政府の資金援助も市場の成長に寄与しています。さらに、がんの早期発見に対する意識の高まりと遺伝子検査サービスの拡大により、ヘルスケア部門全体でNGCDに対する需要が高まっています。

セグメント

技術（qPCR &マルチプレキシング、次世代シーケンシング、LOAC &RT-PCR、その他の技術）、機能（治療モニタリング、コンパニオン診断、予後診断、がんスクリーニング、リスク分析）、用途（バイオマーカー開発、CTC分析、プロテオーム分析、遺伝子分析、その他の用途）

調査対象企業の例（注目の33社）

  • Abbott
  • Agilent Technologies
  • Almac Group
  • Cepheid
  • F. Hoffmann-La Roche Ltd
  • GE Healthcare
  • Genomic Health
  • Hologic
  • Illumina
  • Janssen Global Services
  • Koninklijke Philips N.V
  • Myriad Genetics
  • Novartis AG
  • Opko Health
  • PerkinElmer
  • Qiagen
  • Sysmex Corporation
  • Thermo Fisher Scientific

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP22375

Global Next Generation Cancer Diagnostics Market to Reach US$64.6 Billion by 2030

The global market for Next Generation Cancer Diagnostics estimated at US$19.8 Billion in the year 2024, is expected to reach US$64.6 Billion by 2030, growing at a CAGR of 21.8% over the analysis period 2024-2030. qPCR & Multiplexing Technology, one of the segments analyzed in the report, is expected to record a 22.8% CAGR and reach US$28.2 Billion by the end of the analysis period. Growth in the Next Generation Sequencing Technology segment is estimated at 17.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.7 Billion While China is Forecast to Grow at 21.0% CAGR

The Next Generation Cancer Diagnostics market in the U.S. is estimated at US$5.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$9.9 Billion by the year 2030 trailing a CAGR of 21.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 19.3% and 18.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.8% CAGR.

Global Next Generation Cancer Diagnostics Market - Key Trends and Drivers Summarized

How Are Next Generation Cancer Diagnostics Revolutionizing Oncology?

Next Generation Cancer Diagnostics (NGCD) represent a leap forward in the field of oncology, offering advanced tools for early detection, accurate diagnosis, and personalized treatment of various cancers. These diagnostics encompass a broad range of technologies, including liquid biopsy, genomics, proteomics, and next-generation sequencing (NGS). Unlike traditional diagnostics, NGCDs provide detailed molecular insights, enabling oncologists to understand the genetic mutations and biomarkers that drive cancer progression. This precision enables targeted therapies, improving patient outcomes and reducing side effects. As the prevalence of cancer rises globally, NGCDs are playing a critical role in transforming cancer care by making it more personalized, faster, and more effective.

What Are The Key Segments in the Next Generation Cancer Diagnostics Market?

Key technologies include liquid biopsy, NGS, proteomics, and bioinformatics tools, with liquid biopsy and NGS gaining significant traction due to their non-invasive nature and ability to detect genetic alterations. In terms of applications, NGCDs are used in screening, diagnostic testing, and monitoring treatment response. Screening for early-stage cancers, such as breast, lung, and colorectal cancers, is a major application segment, where early detection significantly improves survival rates. Major end-users of NGCDs include hospitals, diagnostic laboratories, and research institutes, all of which are integrating these technologies into clinical workflows to enhance precision and efficiency in cancer management.

How Are NGCD Technologies Being Integrated Across Healthcare Sectors?

Hospitals and oncology centers are integrating NGCDs into routine cancer screening and diagnostic protocols, particularly for high-risk patients and those with hereditary cancer syndromes. Diagnostic laboratories use NGCDs to perform genomic and proteomic tests that aid in identifying specific mutations and treatment options, supporting precision medicine. Research institutes are leveraging these diagnostics to conduct clinical trials, study cancer genomics, and explore new drug targets. Pharmaceutical companies also collaborate with NGCD developers to identify biomarkers that predict drug efficacy, thereby improving drug development and accelerating clinical trials. Additionally, telehealth platforms are beginning to incorporate NGCDs for remote patient monitoring, making cancer diagnostics more accessible.

What Factors Are Driving the Growth in the Next Generation Cancer Diagnostics Market?

The growth in the Next Generation Cancer Diagnostics market is driven by several factors, including the increasing prevalence of cancer, which has heightened the demand for more effective screening and diagnostic tools. The shift toward personalized medicine, driven by advancements in genomics and proteomics, has further fueled the adoption of NGCDs. The rapid development of liquid biopsy technologies, coupled with improvements in NGS platforms, has enhanced diagnostic accuracy, making NGCDs indispensable in modern oncology. Regulatory approvals and government funding for cancer research and diagnostic innovation are also contributing to market growth. Additionally, the growing awareness of early cancer detection and the expansion of genetic testing services have increased the demand for NGCDs across healthcare sectors.

SCOPE OF STUDY:

The report analyzes the Next Generation Cancer Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Technology (qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR, Other Technologies); Function (Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening, Risk Analysis); Application (Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 33 Featured) -

  • Abbott
  • Agilent Technologies
  • Almac Group
  • Cepheid
  • F. Hoffmann-La Roche Ltd
  • GE Healthcare
  • Genomic Health
  • Hologic
  • Illumina
  • Janssen Global Services
  • Koninklijke Philips N.V
  • Myriad Genetics
  • Novartis AG
  • Opko Health
  • PerkinElmer
  • Qiagen
  • Sysmex Corporation
  • Thermo Fisher Scientific

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Next Generation Cancer Diagnostics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Early and Accurate Cancer Detection Spurs Growth in Next Generation Cancer Diagnostics Market
    • Technological Advancements in Liquid Biopsy and Genomic Testing Strengthen Business Case for Adoption
    • Growing Focus on Personalized and Precision Medicine Expands Addressable Market
    • Expansion of Next Generation Diagnostics in Oncology Clinics and Hospitals Fuels Market Growth
    • Increasing Adoption of Next Generation Diagnostics in Biomarker Discovery and Targeted Therapy Expands Market Opportunities
    • Technological Innovations in Multi-Omics Analysis and AI-Powered Diagnostics Propel Market Expansion
    • Rising Focus on Non-Invasive Testing and Monitoring Drives Demand for Next Generation Cancer Diagnostics
    • Growing Use of Next Generation Diagnostics in Screening Programs and Clinical Trials Expands Market Potential
    • Technological Advancements in ctDNA, CTC, and Circulating miRNA Testing Propel Market Growth
    • Increasing Focus on Integrating Next Generation Cancer Diagnostics with Digital Health Platforms Drives Adoption
    • Rising Demand for Companion Diagnostics in Immuno-Oncology and Targeted Therapies Strengthens Global Market
    • Expansion of Next Generation Cancer Diagnostics in Rare and Pediatric Cancers Expands Market Opportunities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 2: World 6-Year Perspective for Next Generation Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 3: World Recent Past, Current & Future Analysis for qPCR & Multiplexing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 4: World 6-Year Perspective for qPCR & Multiplexing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Next Generation Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World 6-Year Perspective for Next Generation Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for LOAC & RT-PCR by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 8: World 6-Year Perspective for LOAC & RT-PCR by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 9: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 10: World 6-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Biomarker Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World 6-Year Perspective for Biomarker Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for CTC Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 14: World 6-Year Perspective for CTC Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 15: World Recent Past, Current & Future Analysis for Proteomic Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 16: World 6-Year Perspective for Proteomic Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Genetic Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World 6-Year Perspective for Genetic Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 20: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 21: World Recent Past, Current & Future Analysis for Therapeutic Monitoring by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 22: World 6-Year Perspective for Therapeutic Monitoring by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Companion Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World 6-Year Perspective for Companion Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Prognostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 26: World 6-Year Perspective for Prognostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 27: World Recent Past, Current & Future Analysis for Cancer Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 28: World 6-Year Perspective for Cancer Screening by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Risk Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World 6-Year Perspective for Risk Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 31: World Next Generation Cancer Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Next Generation Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA 6-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2025 & 2030
    • TABLE 34: USA Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: USA 6-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2025 & 2030
    • TABLE 36: USA Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: USA 6-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada 6-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2025 & 2030
    • TABLE 40: Canada Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Canada 6-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2025 & 2030
    • TABLE 42: Canada Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Canada 6-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2025 & 2030
  • JAPAN
    • Next Generation Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan 6-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2025 & 2030
    • TABLE 46: Japan Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Japan 6-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2025 & 2030
    • TABLE 48: Japan Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Japan 6-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2025 & 2030
  • CHINA
    • Next Generation Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China 6-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2025 & 2030
    • TABLE 52: China Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: China 6-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2025 & 2030
    • TABLE 54: China Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: China 6-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2025 & 2030
  • EUROPE
    • Next Generation Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe 6-Year Perspective for Next Generation Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 58: Europe Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Europe 6-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2025 & 2030
    • TABLE 60: Europe Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Europe 6-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe 6-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2025 & 2030
  • FRANCE
    • Next Generation Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 64: France Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: France 6-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2025 & 2030
    • TABLE 66: France Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: France 6-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2025 & 2030
    • TABLE 68: France Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France 6-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2025 & 2030
  • GERMANY
    • Next Generation Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 70: Germany Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Germany 6-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2025 & 2030
    • TABLE 72: Germany Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Germany 6-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2025 & 2030
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Germany 6-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2025 & 2030
  • ITALY
    • TABLE 76: Italy Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Italy 6-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2025 & 2030
    • TABLE 78: Italy Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Italy 6-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2025 & 2030
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Italy 6-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2025 & 2030
  • UNITED KINGDOM
    • Next Generation Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 82: UK Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: UK 6-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2025 & 2030
    • TABLE 84: UK Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: UK 6-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2025 & 2030
    • TABLE 86: UK Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: UK 6-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 88: Rest of Europe Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Rest of Europe 6-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2025 & 2030
    • TABLE 90: Rest of Europe Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Rest of Europe 6-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe 6-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Next Generation Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 94: Asia-Pacific Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Asia-Pacific 6-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2025 & 2030
    • TABLE 96: Asia-Pacific Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Asia-Pacific 6-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific 6-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 100: Rest of World Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Technology - qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Rest of World 6-Year Perspective for Next Generation Cancer Diagnostics by Technology - Percentage Breakdown of Value Sales for qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR and Other Technologies for the Years 2025 & 2030
    • TABLE 102: Rest of World Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Application - Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Rest of World 6-Year Perspective for Next Generation Cancer Diagnostics by Application - Percentage Breakdown of Value Sales for Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis and Other Applications for the Years 2025 & 2030
    • TABLE 104: Rest of World Recent Past, Current & Future Analysis for Next Generation Cancer Diagnostics by Function - Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of World 6-Year Perspective for Next Generation Cancer Diagnostics by Function - Percentage Breakdown of Value Sales for Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening and Risk Analysis for the Years 2025 & 2030

IV. COMPETITION